While we propose that expression of these factors is induced as a result of developing tumor hypoxia, it is interesting to note the recent characterization of AR-mediated repression of IL8 gene transcription in prostate cancer cell models, indicating that sustained AR inhibition arising from enzalutamide treatment may also directly contribute to increased IL8 production (23). The gene discussed is CXCL8; the disease is prostate cancer.